[go: up one dir, main page]

DK3310764T3 - Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle - Google Patents

Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle Download PDF

Info

Publication number
DK3310764T3
DK3310764T3 DK16736955.2T DK16736955T DK3310764T3 DK 3310764 T3 DK3310764 T3 DK 3310764T3 DK 16736955 T DK16736955 T DK 16736955T DK 3310764 T3 DK3310764 T3 DK 3310764T3
Authority
DK
Denmark
Prior art keywords
delivery
compositions
individual
cell
agent
Prior art date
Application number
DK16736955.2T
Other languages
English (en)
Inventor
Daniel Griffith Anderson
Joseph R Dorkin
Owen Shea Fenton
Rebecca L Mcclellan
Kevin John Kauffman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK3310764T3 publication Critical patent/DK3310764T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16736955.2T 2015-06-19 2016-06-17 Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle DK3310764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182264P 2015-06-19 2015-06-19
PCT/US2016/038141 WO2016205691A1 (en) 2015-06-19 2016-06-17 Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell

Publications (1)

Publication Number Publication Date
DK3310764T3 true DK3310764T3 (da) 2023-07-17

Family

ID=56404292

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16736955.2T DK3310764T3 (da) 2015-06-19 2016-06-17 Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle

Country Status (17)

Country Link
US (4) US10201618B2 (da)
EP (2) EP4248988A3 (da)
JP (1) JP6800410B2 (da)
CN (2) CN113968823A (da)
AU (3) AU2016278970B2 (da)
CA (1) CA2990172A1 (da)
DK (1) DK3310764T3 (da)
ES (1) ES2949540T3 (da)
FI (1) FI3310764T3 (da)
HR (1) HRP20230494T1 (da)
HU (1) HUE062274T2 (da)
LT (1) LT3310764T (da)
PL (1) PL3310764T3 (da)
PT (1) PT3310764T (da)
RS (1) RS64331B1 (da)
SI (1) SI3310764T1 (da)
WO (1) WO2016205691A1 (da)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
EP4074694A1 (en) 2011-10-27 2022-10-19 Massachusetts Institute Of Technology Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP4248988A3 (en) * 2015-06-19 2023-11-29 Massachusetts Institute of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
KR102424476B1 (ko) 2016-04-19 2022-07-25 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3500671B1 (en) 2016-08-17 2024-07-10 The Broad Institute, Inc. Method of selecting target sequences for the design of guide rnas
US12350368B2 (en) 2017-04-14 2025-07-08 The Broad Institute, Inc. Delivery of large payloads
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US10780183B2 (en) 2017-06-19 2020-09-22 Translate Bio, Inc. Messenger RNA therapy for the treatment of Friedreich's ataxia
US12227742B2 (en) 2017-10-23 2025-02-18 The Broad Institute, Inc. Nucleic acid modifiers
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12221720B2 (en) 2017-11-13 2025-02-11 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
AU2018392716B2 (en) 2017-12-20 2025-03-13 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
AU2019271132A1 (en) 2018-05-15 2020-11-12 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
CN112437767B (zh) 2018-05-24 2023-10-27 川斯勒佰尔公司 硫酯阳离子脂质
CN112384205B (zh) 2018-05-30 2024-05-03 川斯勒佰尔公司 信使rna疫苗及其用途
CA3100214A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
JP7441802B2 (ja) 2018-05-30 2024-03-01 トランスレイト バイオ, インコーポレイテッド ビタミンカチオン性脂質
AU2019277355A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Phosphoester cationic lipids
EP3826608A1 (en) 2018-07-23 2021-06-02 Translate Bio, Inc. Dry power formulations for messenger rna
KR20210091120A (ko) 2018-08-29 2021-07-21 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
US20230145188A1 (en) 2018-09-14 2023-05-11 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
CA3112837A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
JP7483294B2 (ja) * 2018-11-09 2024-05-15 トランスレイト バイオ, インコーポレイテッド 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む2,5-ジオキソピペラジン脂質
CA3117866A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
EP3876994A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Peg lipidoid compounds
US20220016265A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
AU2019378763B2 (en) 2018-11-12 2025-06-26 Translate Bio, Inc. Methods for inducing immune tolerance
WO2020106903A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
CN113544266A (zh) 2018-12-17 2021-10-22 博德研究所 Crispr相关转座酶系统和其使用方法
US20220087935A1 (en) 2019-01-07 2022-03-24 Translate Bio, Inc. Composition and Methods for Treatment of Primary Ciliary Dyskinesia
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
EP3956303A1 (en) 2019-04-18 2022-02-23 Translate Bio, Inc. Cystine cationic lipids
ES2972014T3 (es) 2019-04-22 2024-06-10 Translate Bio Inc Lípidos catiónicos de tioéster
US12453759B2 (en) 2019-05-03 2025-10-28 Translate Bio, Inc. Di-thioester cationic lipids
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2020243540A1 (en) 2019-05-31 2020-12-03 Translate Bio, Inc. Macrocyclic lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
CN117945938A (zh) 2019-06-21 2024-04-30 川斯勒佰尔公司 三(羟甲基)甲基甘氨酸和柠檬酸脂质
KR20220078557A (ko) * 2019-07-08 2022-06-10 트랜슬레이트 바이오 인코포레이티드 개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
MX2022000934A (es) 2019-07-23 2022-02-14 Translate Bio Inc Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion.
AU2020348376A1 (en) 2019-09-20 2022-04-07 Translate Bio, Inc. mRNA encoding engineered CFTR
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
WO2021081058A1 (en) 2019-10-21 2021-04-29 Translate Bio, Inc. Compositions, methods and uses of messenger rna
CA3162368A1 (en) 2019-12-20 2021-06-24 Shrirang KARVE Rectal delivery of messenger rna
AU2020405214A1 (en) 2019-12-20 2022-08-11 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
EP4110296A1 (en) 2020-02-25 2023-01-04 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
CN113527216B (zh) * 2020-04-21 2025-03-21 上海惠永药物研究有限公司 一种二酮基哌嗪类化合物的制备方法,其中间体及制备方法
EP4146265A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Optimized nucleotide sequences encoding sars-cov-2 antigens
US20230181619A1 (en) 2020-05-07 2023-06-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
US20230226219A1 (en) 2020-05-14 2023-07-20 Translate Bio, Inc. Peg lipidoid compounds
JP2023526284A (ja) 2020-05-15 2023-06-21 トランスレイト バイオ, インコーポレイテッド mRNA送達のための脂質ナノ粒子製剤
AU2021275223A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Coronavirus antigen compositions and their uses
CA3179444A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Immunogenic compositions and uses thereof
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
KR20230029685A (ko) 2020-05-29 2023-03-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Trem 조성물 및 이에 관련된 방법
WO2022006527A1 (en) 2020-07-02 2022-01-06 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
IL299847A (en) 2020-07-21 2023-03-01 Chembeau LLC Cosmetic diester formulations and their uses
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
US20230357166A1 (en) * 2020-09-23 2023-11-09 Translate Bio, Inc. Piperazine-based cationic lipids
CA3194863A1 (en) 2020-10-06 2022-04-14 Shrirang KARVE Improved process and formulation of lipid nanoparticles
US20220133631A1 (en) 2020-10-12 2022-05-05 Translate Bio, Inc. Process of preparing ice-based lipid nanoparticles
CA3198411A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
CN116406299A (zh) * 2020-11-06 2023-07-07 赛诺菲 用于递送mRNA疫苗的脂质纳米颗粒
TW202233232A (zh) * 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
WO2022099194A1 (en) 2020-11-09 2022-05-12 Translate Bio, Inc. Improved compositions for delivery of codon-optimized mrna
IL303165A (en) 2020-11-25 2023-07-01 Translate Bio Inc Stable liquid lipid nanoparticle formulations
KR20230135585A (ko) 2020-12-23 2023-09-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 trem의 조성물 및 이의 용도
JP2024500515A (ja) * 2020-12-24 2024-01-09 エンハンストバイオ インコーポレイテッド 脂質ナノ粒子を含む癌の予防または治療用組成物
KR102537540B1 (ko) * 2020-12-24 2023-05-26 (주)인핸스드바이오 만노스를 포함하는 지질 나노입자 또는 이의 용도
EP4277929A1 (en) 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
AU2021425941A1 (en) 2021-02-08 2023-08-17 The Board Of Regents Of The University Of Texas System Unsaturated dendrimers compositions,related formulations, and methods of use thereof
BR112023019229A2 (pt) 2021-03-22 2023-11-28 Recode Therapeutics Inc Composições e métodos para a liberação direcionada às células
IL306007A (en) 2021-03-23 2023-11-01 Recode Therapeutics Inc Polynucleotide preparations, related formulations and methods of using them
EP4313115A1 (en) 2021-03-25 2024-02-07 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
EP4326338A1 (en) 2021-04-19 2024-02-28 Translate Bio, Inc. Improved compositions for delivery of mrna
JP7781448B2 (ja) * 2021-05-28 2025-12-08 北京啓辰生生物科技有限公司 脂質化合物及び核酸送達におけるその応用
JP2024528418A (ja) 2021-06-18 2024-07-30 サノフイ 多価インフルエンザワクチン
US20250001002A1 (en) 2021-07-01 2025-01-02 Translate Bio, Inc. Compositions for delivery of mrna
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
CN113603874B (zh) * 2021-07-28 2022-11-01 武汉科技大学 基于香草醇衍生物的聚酯、制备及用作农药缓释剂
EP4464783A3 (en) 2021-09-17 2025-01-22 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
EP4412590A1 (en) 2021-10-05 2024-08-14 Sanofi Methods for freezing and freeze-drying lipid nanoparticles (lnps) and lnps obtained with the same
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
EP4419081A1 (en) 2021-10-22 2024-08-28 Sail Biomedicines, Inc. Mrna vaccine composition
WO2023079507A1 (en) 2021-11-05 2023-05-11 Sanofi Respiratory syncytial virus rna vaccine
WO2023086893A1 (en) 2021-11-10 2023-05-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
IL312799A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions of varicella-zoster virus and uses thereof
IL313004A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Coronavirus immunogen compositions and their uses
EP4436598A2 (en) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and their uses
IL312997A (en) 2021-11-30 2024-07-01 Sanofi Pasteur Inc Human metapneumovirus vaccines
EP4448758A1 (en) 2021-12-17 2024-10-23 Flagship Pioneering Innovations VI, LLC Methods for enrichment of circular rna under denaturing conditions
EP4448103A1 (en) 2021-12-17 2024-10-23 Sanofi Lyme disease rna vaccine
AU2022421841A1 (en) 2021-12-20 2024-06-27 Sail Biomedicines, Inc. Mrna therapeutic compositions
CA3241061A1 (en) 2021-12-22 2023-06-29 Alexandra Sophie DE BOER Compositions and methods for purifying polyribonucleotides
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
TW202345835A (zh) * 2022-03-16 2023-12-01 美商轉譯生技公司 非對稱的基於哌嗪之陽離子脂質
KR20240166554A (ko) 2022-03-25 2024-11-26 세일 바이오메디슨스, 인크. 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
KR20250008765A (ko) 2022-05-06 2025-01-15 사노피 핵산 백신에 대한 신호 서열
EP4522743A1 (en) 2022-05-09 2025-03-19 Flagship Pioneering Innovations VI, LLC Trem compositions and methods of use for treating proliferative disorders
JP2025516638A (ja) 2022-05-13 2025-05-30 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 二本鎖dna組成物及び関連する方法
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
AU2023320333A1 (en) 2022-08-01 2025-01-16 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024028492A1 (en) 2022-08-04 2024-02-08 Sanofi Quantitative assessment of rna encapsulation
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
CN120813372A (zh) 2022-08-22 2025-10-17 促进军事医学的亨利·M·杰克逊基金会公司 针对冠状病毒的疫苗
KR20250056256A (ko) 2022-08-31 2025-04-25 세일 바이오메디슨스, 인크. 신규 이온화성 지질 및 지질 나노입자, 그리고 이의 사용 방법
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4612296A1 (en) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
JP2025537539A (ja) 2022-11-04 2025-11-18 サノフィ パスツール インコーポレイテッド 呼吸器合胞体ウイルスrnaワクチン接種
AR131008A1 (es) 2022-11-08 2025-02-05 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
CN120359023A (zh) 2022-11-10 2025-07-22 赛欧生物医药股份有限公司 包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物
JP2025538523A (ja) 2022-11-21 2025-11-28 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの乾燥粉末製剤の組成物及びその使用方法
WO2024123633A1 (en) 2022-12-08 2024-06-13 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
EP4633673A1 (en) 2022-12-15 2025-10-22 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
EP4648794A2 (en) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫調節組合物及相關方法
EP4665736A2 (en) 2023-02-13 2025-12-24 Flagship Pioneering Innovations VII, LLC Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
EP4665856A2 (en) 2023-02-17 2025-12-24 Flagship Pioneering Innovations VII, LLC Dna compositions comprising modified cytosine
IL322201A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
TW202502375A (zh) 2023-03-02 2025-01-16 法商賽諾菲公司 用於治療披衣菌之組合物
AU2024235803A1 (en) 2023-03-15 2025-09-25 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
AU2024255972A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
AU2024256347A1 (en) 2023-04-17 2025-11-27 Sanofi Pasteur Inc. Reconstitutable dry powder formulations and methods of use thereof
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
TW202500750A (zh) 2023-05-05 2025-01-01 法商賽諾菲公司 用於治療痤瘡的組成物
AR132662A1 (es) 2023-05-10 2025-07-16 Sanofi Sa Combinación de vacunas respiratorias de arnm
WO2024246358A1 (en) 2023-06-01 2024-12-05 Sanofi Thermostable compositions comprising mrna lipid nanoparticles
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025003760A1 (en) 2023-06-28 2025-01-02 Sanofi Sterol analogs in lipid nanoparticle formulations
AR133317A1 (es) 2023-07-19 2025-09-17 Sanofi Sa Constructos antigénicos de porphyromonas gingivalis
TW202516001A (zh) 2023-07-25 2025-04-16 美商旗艦先鋒創新有限責任(Vii)公司 Cas內切酶及相關方法
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾b型流感血球凝集素多肽及核酸及其用途
WO2025064475A2 (en) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任(Vii)公司 可電離類脂質組成物及其治療用途
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
CN120227354A (zh) * 2023-12-29 2025-07-01 康希诺(上海)生物研发有限公司 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025217298A1 (en) * 2024-04-10 2025-10-16 Georgia Tech Research Corporation Novel lipids containing diketopiperazine core, lipid nanoparticle containing thereof, and methods of using thereof
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025250808A1 (en) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Anti-crispr delivery compositions and methods

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759021A (en) 1951-01-19 1956-08-14 Armour & Co Substituted trimethylene diamines
US2844629A (en) 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
US3127372A (en) 1960-10-05 1964-03-31 Stabilization of polyolefevs
DE1155118B (de) 1961-12-30 1963-10-03 Basf Ag Verfahren zur Herstellung von am Stickstoffatom substituierten Sulfonamiden
DE1191629B (de) 1962-03-16 1965-04-22 Basf Ag Fungizide Mittel
US3354209A (en) 1964-02-19 1967-11-21 Hercules Inc Poly(dihydroxyalkyl) tertiary amines
JPS515430B1 (da) 1971-05-10 1976-02-19
GB1361627A (en) 1970-08-04 1974-07-30 Marumo H Detergent composition
US3964861A (en) 1971-12-23 1976-06-22 Allied Chemical Corporation Alkoxylated aliphatic amines to inhibit ozone fading of dyed polyamides
JPS5122416B2 (da) 1972-11-11 1976-07-09
US4022833A (en) 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
JPS49127908A (da) 1973-04-20 1974-12-07
JPS5123537A (ja) 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd Kasozaisoseibutsu
JPS5813576B2 (ja) 1974-12-27 1983-03-14 アデカ ア−ガスカガク カブシキガイシヤ 安定化された合成高分子組成物
DE2520814A1 (de) 1975-05-09 1976-11-18 Bayer Ag Lichtstabilisierung von polyurethanen
US4265745A (en) 1977-05-25 1981-05-05 Teijin Limited Permselective membrane
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
JPS5682859A (en) 1979-12-11 1981-07-06 Sakura Color Prod Corp Ink composition
US4308085A (en) 1980-07-28 1981-12-29 Jenoptik Jena Gmbh Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts
JPS588770A (ja) 1981-07-09 1983-01-18 Sakura Color Prod Corp ジヱツト印刷用インキ組成物
GB8413911D0 (en) 1984-05-31 1984-07-04 British Petroleum Co Plc Encapsulating organic material
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1320724C (en) 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
ATE77806T1 (de) 1985-08-05 1992-07-15 Miyoshi Yushi Kk Verfahren fuer die abscheidung von metallen.
EP0233140B1 (de) 1986-01-10 1989-11-08 Ciba-Geigy Ag Schwefel-und stickstoffhaltige Schmiermittelzusätze
DE3616824A1 (de) 1986-05-17 1987-11-19 Schering Ag Verwendung von haertbaren kunstharzmischungen fuer oberflaechenbeschichtungen und druckfarben und verfahren zu ihrer herstellung
US4778825A (en) 1986-08-29 1988-10-18 The University Of Akron Macrophage stimulation by quadrol
US4720517A (en) 1986-11-24 1988-01-19 Ciba-Geigy Corporation Compositions stabilized with N-hydroxyiminodiacetic and dipropionic acids and esters thereof
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4873370A (en) 1987-03-03 1989-10-10 Pennzoil Products Company Alkylene diamines for use in friction and wear reducing compositions
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
JPH07116064B2 (ja) 1987-07-21 1995-12-13 三菱化学株式会社 分離剤
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JP2684276B2 (ja) 1991-11-27 1997-12-03 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE4218744C2 (de) 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5380778A (en) 1992-09-30 1995-01-10 Minnesota Mining And Manufacturing Company Fluorochemical aminoalcohols
JPH06211978A (ja) 1992-10-28 1994-08-02 Takeda Chem Ind Ltd 新規ポリエーテルポリオール及びそれを用いる軟質ウレタンフォームの製造法
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
RU2143903C1 (ru) 1993-02-19 2000-01-10 Ниппон Синяку Ко., Лтд. Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты
US5624976A (en) 1994-03-25 1997-04-29 Dentsply Gmbh Dental filling composition and method
FR2707289B1 (fr) 1993-07-06 1995-08-11 Chemoxal Sa Procédé de préparation d'un composé hydroxylé d'amine secondaire ou tertiaire.
CA2176714A1 (en) 1993-11-24 1995-06-01 Timothy D. Heath Amphiphilic derivatives of piperazine
US5464924A (en) 1994-01-07 1995-11-07 The Dow Chemical Company Flexible poly(amino ethers) for barrier packaging
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
JPH0913066A (ja) 1995-06-26 1997-01-14 Kao Corp ディーゼルエンジン用潤滑油添加剤及び潤滑油組成物
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
DE19541788A1 (de) 1995-11-09 1997-05-15 Max Planck Gesellschaft Fluoralkylmodifizierte polyhydroxylierte Kohlenwasserstoffe
FR2741066B1 (fr) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JPH10197978A (ja) 1997-01-09 1998-07-31 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JPH115786A (ja) 1997-06-13 1999-01-12 Pola Chem Ind Inc 新規アミノヒドロキシプロピルピペラジン誘導体
JPH11106329A (ja) 1997-08-04 1999-04-20 Ajinomoto Co Inc 化粧料組成物
JPH1180142A (ja) 1997-09-05 1999-03-26 Pola Chem Ind Inc ジフェニルアルキル化合物の製造法
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
FR2774092B1 (fr) 1998-01-26 2000-02-18 Air Liquide Procede de preparation de polyazacycloalcanes greffes sur gel de silice et utilisation des composes greffes
DE19822602A1 (de) 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
CN1433478A (zh) 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
IL138474A0 (en) 2000-09-14 2001-10-31 Epox Ltd Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6656977B2 (en) 2001-07-20 2003-12-02 Air Products And Chemical, Inc. Alkyl glycidyl ether-capped polyamine foam control agents
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
US7563857B2 (en) 2002-11-04 2009-07-21 Momentive Performance Materials Gmbh Linear polyamino and/or polyammonium polysiloxane copolymers I
EP1572669A2 (en) 2002-11-22 2005-09-14 Novo Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
US6998508B2 (en) 2003-03-10 2006-02-14 Air Products And Chemicals, Inc. Tertiary alkanolamines containing surface active alkyl groups
US6737485B1 (en) 2003-04-22 2004-05-18 E. I. Du Pont De Nemours And Company Titanium chelate dispersions
US6781537B1 (en) 2003-06-10 2004-08-24 Nortel Networks Limited High speed digital to analog converter
EP1644479A4 (en) 2003-06-16 2008-04-23 Mark W Grinstaff MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION
JP2005041845A (ja) 2003-07-25 2005-02-17 Kawaken Fine Chem Co Ltd N−(2−ヒドロキシアルキル)−n−アルキルアミノカルボン酸組成物、それを含有する界面活性剤用刺激緩和剤および該組成物の製造方法
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
PL1737899T3 (pl) 2004-04-20 2016-01-29 Dendritic Nanotechnologies Inc Polimery dendrytyczne o ulepszonej amplifikacji i wewnętrznych grupach funkcyjnych
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
DE102004043342A1 (de) 2004-09-08 2006-03-09 Bayer Materialscience Ag Blockierte Polyurethan-Prepolymere als Klebstoffe
GB0502482D0 (en) 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
WO2006105043A2 (en) 2005-03-28 2006-10-05 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
ITMI20051155A1 (it) 2005-06-20 2006-12-21 Maflon S R L Nuovi composti fluorurati, loro sintesi e uso.
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US20090221684A1 (en) 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
CN100569877C (zh) 2005-12-30 2009-12-16 财团法人工业技术研究院 含多uv交联反应基的分枝状结构化合物及其应用
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
CA2654302A1 (en) 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (es) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
US8071082B2 (en) 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
EP2094640A4 (en) 2006-11-01 2015-05-20 Pronova Biopharma Norge As ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR)
US8124802B2 (en) 2007-01-26 2012-02-28 Jenrin Discovery, Inc. MAO inhibiting N-benzyl-N-propargyl-amines useful for treating obesity
WO2008113364A2 (en) 2007-03-20 2008-09-25 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
JP5186126B2 (ja) 2007-03-29 2013-04-17 公益財団法人地球環境産業技術研究機構 新規トリアジン誘導体ならびにその製法およびそのガス分離膜としての用途
US8678686B2 (en) 2007-05-01 2014-03-25 Pgr-Solutions Multi-chain lipophilic polyamines
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
JP2009087966A (ja) 2007-09-27 2009-04-23 Fujifilm Corp 金属用研磨液及びそれを用いた研磨方法
WO2009046220A2 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
WO2009086547A1 (en) 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
DK2242752T3 (da) 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
WO2010062322A2 (en) 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
WO2010074268A1 (ja) 2008-12-26 2010-07-01 日油株式会社 アルギニン誘導体およびこれを含有する化粧料
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2531009T3 (es) 2008-12-29 2015-03-09 Mannkind Corp Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
US8835368B2 (en) 2009-02-18 2014-09-16 The Lubrizol Corporation Compounds and a method of lubricating an internal combustion engine
US20100222489A1 (en) 2009-02-27 2010-09-02 Jiang Dayue D Copolymer composition, membrane article, and methods thereof
EP2415124B1 (en) 2009-04-02 2017-02-15 The Siemon Company Telecommunications patch panel
KR102229618B1 (ko) 2009-05-05 2021-03-18 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
US20120196923A1 (en) 2009-05-15 2012-08-02 Kaushal Rege Polymers for delivering a substance into a cell
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2769408C (en) 2009-07-30 2017-09-05 Laboratorios Salvat, S.A. Apaf-1 inhibitor compounds
CA2782676C (en) 2009-12-01 2021-06-15 Shire Human Genetic Therapies, Inc. Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
EP2509922A2 (en) 2009-12-11 2012-10-17 Chemseq Internatiopnal Ab Methods and compositions for complex binding of metal ions
CN101863544B (zh) 2010-06-29 2011-09-28 湖南科技大学 一种氰尿酸基重金属螯合絮凝剂及其制备方法
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
WO2012133737A1 (ja) 2011-03-31 2012-10-04 公益財団法人地球環境産業技術研究機構 架橋性アミン化合物、該化合物を用いた高分子膜及びその製造方法
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CN103748078B (zh) 2011-06-08 2016-11-09 夏尔人类遗传性治疗公司 可裂解脂质
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CL2014000988A1 (es) 2011-10-20 2014-11-03 Oryzon Genomics Sa Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
EP4074694A1 (en) 2011-10-27 2022-10-19 Massachusetts Institute Of Technology Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
JP5991937B2 (ja) 2013-03-06 2016-09-14 Jxエネルギー株式会社 摩擦調整剤および潤滑油組成物
RS62565B1 (sr) * 2013-03-14 2021-12-31 Translate Bio Inc Metode i kompozicije za isporuku antitela kodiranih od strane irnk
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
KR101355583B1 (ko) 2013-10-04 2014-01-24 한국지질자원연구원 간이 유용광물 분리 장치 및 이를 이용한 유용광물 분리 방법
CA2928040A1 (en) * 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
EP3871696B1 (en) 2013-10-22 2025-03-19 Translate Bio, Inc. Lipid formulations for delivery of messenger rna
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP4248988A3 (en) * 2015-06-19 2023-11-29 Massachusetts Institute of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell

Also Published As

Publication number Publication date
EP3310764B1 (en) 2023-04-19
AU2016278970A1 (en) 2018-01-18
US20230338577A1 (en) 2023-10-26
AU2022259755B2 (en) 2024-06-27
US20190240349A1 (en) 2019-08-08
EP3310764A1 (en) 2018-04-25
US10695444B2 (en) 2020-06-30
ES2949540T3 (es) 2023-09-29
HUE062274T2 (hu) 2023-10-28
AU2021200199B2 (en) 2022-07-28
HRP20230494T1 (hr) 2023-08-04
US11679165B2 (en) 2023-06-20
RS64331B1 (sr) 2023-08-31
FI3310764T3 (fi) 2023-07-18
PL3310764T3 (pl) 2023-11-06
US10201618B2 (en) 2019-02-12
US20160367686A1 (en) 2016-12-22
CN113968823A (zh) 2022-01-25
CN107848988B (zh) 2021-10-22
HK1251901A1 (en) 2019-04-26
WO2016205691A1 (en) 2016-12-22
PT3310764T (pt) 2023-07-11
AU2016278970B2 (en) 2020-10-29
JP2018519285A (ja) 2018-07-19
US20200353099A1 (en) 2020-11-12
JP6800410B2 (ja) 2020-12-16
AU2021200199A1 (en) 2021-03-18
CN107848988A (zh) 2018-03-27
LT3310764T (lt) 2023-06-12
EP4248988A3 (en) 2023-11-29
AU2022259755A1 (en) 2022-12-01
SI3310764T1 (sl) 2023-06-30
CA2990172A1 (en) 2016-12-22
EP4248988A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
DK3310764T3 (da) Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
DK3439653T3 (da) Reduktion af tumorbyrde ved administration af ccr1- antagonister i kombination med pd-1-hæmmere eller pd-l1-hæmmere
DK3434762T3 (da) Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK3332438T3 (da) Redox-flow-celle til lagring af elektrisk energi og anvendelse deraf
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
SI3194570T1 (sl) Postopki in sestavki za genomski inženiring s posredovanjem nukleaze in korekcijo krvotvornih matičnih celic
DK3207124T3 (da) Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
DK3143127T3 (da) Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
BR112016020618A2 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
EP2971116A4 (en) GENE EXPRESSION OF DENDRITIC CELL REACTION, SUBSTANCE COMPOSITIONS AND METHOD FOR USE THEREOF
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3319587T3 (da) Ny farmaceutisk sammensætning der omfatter partikler som omfatter et kompleks af et dobbelstrenget polyribonucleotid og en polyalkylenimin
DK3350162T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
PL3394248T3 (pl) Kompozycja komórek dendrytycznych
DK3244886T3 (da) Indolderivater som inhibitorer af dengue virus-replikation
PL3154515T3 (pl) Udoskonalenia kompozycji donosowych i sposób ich stosowania
SI3710036T1 (sl) Stabilni sestavki askorbinske kisline in postopki njihove uporabe
IL282220B (en) Genetically-engineered drug resistant t cells and methods of using the same
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
IL249453B (en) Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
BR112016019954A2 (pt) composição de fibra de vidro, fibra de vidro e material compósito do mesmo